Monopar initiates Phase 1 dosimetry trial for MNPR-101-Zr in advanced cancers

Monopar Therapeutics

Trial open for enrollment at Melbourne Theranostic Innovation Centre; led by Prof. Rodney Hicks.
Evaluating safety/dosimetry in up to 12 advanced cancer patients using total-body PET/CT scanner.
MNPR-101 targets uPAR expressed on pancreatic, breast, colorectal, and bladder tumors.
Preclinical data show specific tumor uptake; if Phase 1 positive, plan to test MNPR-101 with therapeutic Ac-225.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.